產(chǎn)品屬性：
產(chǎn)品名稱(chēng) | Tolcapone-d4 |
規(guī)格 | 1mg |
貨號(hào) | EY-01Y15390 |
Cas No.: 1246816-93-2
別名: N/A
化學(xué)名: N/A
分子式: C14H7D4NO5
分子量: 277.3
溶解度: DMSO: slightly soluble,Methanol: slightly soluble
儲(chǔ)存條件: Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述：
Tolcapone-d4 is intended for use as an internal standard for the quantification of tolcapone by GC- or LC-MS. Tolcapone is a reversible inhibitor of catechol-O-methyltransferase (COMT; Ki = 0.27 nM for human recombinant COMT), an enzyme that degrades catecholamines, including dopamine and L-DOPA .1,2 Tolcapone crosses the blood brain barrier and can inhibit both peripheral and central COMT activity.3,4 By inhibiting COMT, tolcapone increases L-DOPA efficacy and reduces L-DOPA-induced motor complications in animal models of Parkinson's disease.3|1. Lotta, T., Vidgren, J., Tilgmann, C., et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: A revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34(13), 4202-4210 (1995).|2. M?nnist?, P.T., and Kaakkola, S. Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev. 51(4), 593-628 (1999).|3. Espinoza, S., Managó, F., Leo, D., et al. Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson's disease and L-DOPA treatment. CNS Neurol. Disord. Drug Targets 11(3), 251-263 (2012).|4. M?nnist?, P.T., Tuomainen, P., and Tuominen, R.K. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat. Br. J. Pharmacol. 105(3), 569-574 (1992).
特別提醒公司產(chǎn)品僅供科研使用
